Cisplatin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1978
- First approval year
- 1978
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Cisplatin
- Molecular weight
- 300.05
- Structure (SMILES)
These details could not be displayed.
- cisplatin
- Cisplatin
- platinol
- Platinol
- platinol aq
- Platinol-aq
- (sp-4-2)-diamminedichloroplatinum
- (SP-4-2)-DIAMMINEDICHLOROPLATINUM [WHO-IP]
- 5 fluorouracil and cisplatin
- cddp
- CDDP
- cis ddp
- cis diamminedichloroplatinum
- cis diamminedichloroplatinum ii
- cis diamminedichloroplatinum who ip
- cis platin
- cis platinum ii
- CIS-DDP
- cis-diamminedichloroplatinum
- Cis-diamminedichloroplatinum
- CIS-DIAMMINEDICHLOROPLATINUM [WHO-IP]
- Cis-diamminedichloroplatinum ii
- Cis-diamminedichloroplatinum(ii)
- Cis-platin
- Cis-platinum ii
- cisplatin
- Cisplatin
- CISPLATIN
- Cisplatin - Dose Level 1
- Cisplatin - Dose Level 2
- Cisplatin (arm B)
And 87 more, listed on the interactive page.
- ATC classification codes
- L01XA01
Sources for recorded values
- CAS registry numbers
- 15663-27-1
- ChEMBL ID
- CHEMBL11359
- InChIKey
- LXZZYRPGZAFOLE-UHFFFAOYSA-L
- RxNorm IDs (RxCUI)
- 2555
- FDA ingredient codes (UNII)
- Q20Q21Q62J
- Applicant
- HQ SPCLT PHARMA
- Approval date
- 19 Dec 1978
- Application number
- NDA018057
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- cisplatin
- Type
- Inorganic
- Drug name stem
- -platin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Carcinoma, Endometrioid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000466
- Subject identifier
- D018269
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
And 170 more, listed on the interactive page.
- Condition identifier
- EFO_0000096
- Condition identifier
- EFO_0000178
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000228
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000294
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000365
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000478
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000514
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000571
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000588
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000637
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
And 404 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- anaemia
- Reports
- 3,609
- Reporting signal score
- 2,285.27
- Event
- bone marrow failure
- Reports
- 990
- Reporting signal score
- 1,175.02
- Event
- dehydration
- Reports
- 2,241
- Reporting signal score
- 1,547.06
- Event
- disease progression
- Reports
- 1,979
- Reporting signal score
- 1,584.87
- Event
- febrile neutropenia
- Reports
- 4,144
- Reporting signal score
- 6,893.02
- Event
- haematotoxicity
- Reports
- 706
- Reporting signal score
- 1,230.65
- Event
- hypokalaemia
- Reports
- 1,223
- Reporting signal score
- 1,030.98
- Event
- hypomagnesaemia
- Reports
- 629
- Reporting signal score
- 779.316
- Event
- hyponatraemia
- Reports
- 602
- Reporting signal score
- 397.926
- Event
- injection site pain
- Reports
- 9
- Reporting signal score
- 782.24
- Event
- leukopenia
- Reports
- 1,525
- Reporting signal score
- 1,353.17
- Event
- malignant neoplasm progression
- Reports
- 1,839
- Reporting signal score
- 1,940.62
- Event
- mucosal inflammation
- Reports
- 1,608
- Reporting signal score
- 2,429.2
- Event
- myelosuppression
- Reports
- 760
- Reporting signal score
- 1,266.43
- Event
- nausea
- Reports
- 4,946
- Reporting signal score
- 818.172
- Event
- nephropathy toxic
- Reports
- 345
- Reporting signal score
- 558.111
- Event
- neutropenia
- Reports
- 4,381
- Reporting signal score
- 4,493.9
- Event
- neutropenic sepsis
- Reports
- 541
- Reporting signal score
- 1,007.99
- Event
- neutrophil count decreased
- Reports
- 1,375
- Reporting signal score
- 1,522.12
- Event
- ototoxicity
- Reports
- 154
- Reporting signal score
- 377.418
- Event
- pancytopenia
- Reports
- 1,684
- Reporting signal score
- 1,694.5
- Event
- pulmonary embolism
- Reports
- 646
- Reporting signal score
- 372.455
- Event
- pyrexia
- Reports
- 3,117
- Reporting signal score
- 789.413
- Event
- stomatitis
- Reports
- 474
- Reporting signal score
- 365.11
- Event
- thrombocytopenia
- Reports
- 3,188
- Reporting signal score
- 2,697.87
And 1 more, listed on the interactive page.
- NCT00001426
- NCT00772863
- NCT00919984
- NCT00001450
- NCT00001499
- NCT00042835
- NCT00055757
- NCT00069875
- NCT00070629
- NCT00077883
- NCT00082472
- NCT00087711
- NCT00130780
- NCT00148395
- NCT00148798
- NCT00154739
- NCT00167401
- NCT00173888
- NCT00190476
- NCT00191126
- NCT00191139
- NCT00191230
- NCT00191308
- NCT00191490
- NCT00191620
And 2,230 more, listed on the interactive page.
- Dose
- 75-100 mg/m2
- Route
- Intravenous
- How often
- Once every 4 weeks
- Administer as slow infusion
- Do not dilute in 5% Dextrose Injection without saline
- Do not give by rapid bolus
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 5
- Molecular formula
- H6Cl2N2Pt+2
- Monoisotopic mass
- 298.955598
- Natural product
- No
- 0143-9504
- 0143-9505
- 0703-5747
- 0703-5748
- 16729-288
- 25021-253
- 44567-509
- 44567-510
- 44567-511
- 44567-530
- 63323-103
- 68001-283
- 68001-608
- 68001-609
- 68083-162
- 68083-163
- 72266-252
- 72266-253
- 60505-6279
Solubility
- Median
- 31
- Mean
- 31
- Minimum
- 31
- Maximum
- 31
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Liver toxicity assay
- Median
- 770
- Mean
- 770
- Minimum
- 770
- Maximum
- 770
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Related records
Trials (3,344)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
- 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
- 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- 7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
- 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Approved for (2)
- Cancer
- Neoplasm
In development for (192)
- Adenocarcinoma Phase 3
- Adrenal cortex carcinoma Phase 3
- Adult T-cell leukemia/lymphoma Phase 2
- Anaplastic ependymoma Phase 3
- Anaplastic large cell lymphoma Phase 2
- Anemia Phase 3
- Angioimmunoblastic T-cell lymphoma Phase 2
- Anus cancer Phase 3
- Basal cell carcinoma Phase 1
- Bile duct cancer Phase 2
- Biliary tract cancer Phase 3
- Biliary tract neoplasm Phase 3
- Brain cancer Phase 3
- Brain neoplasm Phase 3
- Breast cancer Phase 3
- Breast carcinoma Phase 3
- Breast neoplasm Phase 3
- Carcinoid tumor Phase 2
- Carcinoma Phase 3
- Carcinoma of esophagus Phase 3
Other linked conditions (1)
- Vulvar carcinoma